应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PBE INVESCO BIOTECHNOLOGY & GENOME ETF
休市中 07-31 16:00:00 EDT
89.61
-1.49
-1.64%
盘后
89.68
+0.07
+0.08%
19:34 EDT
最高
89.68
最低
88.62
成交量
2,625
今开
89.00
昨收
91.10
日振幅
1.16%
总市值
2.81亿
流通市值
2.81亿
总股本
314.00万
成交额
23.42万
换手率
0.08%
流通股本
314.00万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
安进：部分数据已遭窃取，其中包括专有数据、患者受保护健康信息及其他信息。
智通财经 · 08-01 04:12
安进：部分数据已遭窃取，其中包括专有数据、患者受保护健康信息及其他信息。
安进：相关调查仍在进行中。
智通财经 · 08-01 04:06
安进：相关调查仍在进行中。
安进：预计这一事件不会对公司财务状况或经营业绩产生重大影响。
智通财经 · 08-01 04:05
安进：预计这一事件不会对公司财务状况或经营业绩产生重大影响。
安进在提交给美国证券交易委员会的文件中披露：其云环境中发生专有信息与患者数据泄露事件。截至2026年7月29日判定此次网
智通财经 · 08-01 04:05
安进在提交给美国证券交易委员会的文件中披露：其云环境中发生专有信息与患者数据泄露事件。截至2026年7月29日判定此次网
阿尔尼拉姆制药公司公布2026年第二季度财报，并重点回顾近期阶段性进展
美股速递 · 07-30 20:02
阿尔尼拉姆制药公司公布2026年第二季度财报，并重点回顾近期阶段性进展
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
美股速递 · 07-29
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器
美股速递 · 07-29
AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器
渤健公司：因整合Apellis，截至2026年6月30日止三个月及六个月确认1.532亿美元税前重组净支出
美股速递 · 07-29
渤健公司：因整合Apellis，截至2026年6月30日止三个月及六个月确认1.532亿美元税前重组净支出
渤健公司：中东冲突未对2026年上半年经营业绩产生实质性影响
美股速递 · 07-29
渤健公司：中东冲突未对2026年上半年经营业绩产生实质性影响
渤健：高剂量Spinraza转换进度超预期，已覆盖所有已上市地区
美股速递 · 07-29
渤健：高剂量Spinraza转换进度超预期，已覆盖所有已上市地区
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
每日经济新闻 · 07-28
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
新浪医药 · 07-23
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
创新药研发加速遇“猴荒”
三里河 · 07-22
创新药研发加速遇“猴荒”
Royalty Pharma宣布2026年第三季度股息派发
投资观察 · 07-18
Royalty Pharma宣布2026年第三季度股息派发
卫材：加拿大药品管理机构认可Leqembi临床价值，建议将早期阿尔茨海默病纳入公共医保覆盖
美股速递 · 07-16
卫材：加拿大药品管理机构认可Leqembi临床价值，建议将早期阿尔茨海默病纳入公共医保覆盖
a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO
智通财经 · 07-15
a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO
Leqembi®真实世界领先研究在AAIC® 2026发布：超75%早期阿尔茨海默病患者在平均17个月治疗期内保持稳定，近7%出现改善
美股速递 · 07-14
Leqembi®真实世界领先研究在AAIC® 2026发布：超75%早期阿尔茨海默病患者在平均17个月治疗期内保持稳定，近7%出现改善
渤健公司于AAIC公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益与强劲Tau蛋白降低
美股速递 · 07-14
渤健公司于AAIC公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益与强劲Tau蛋白降低
百健(BIIB.US)：将推进阿尔茨海默病药物Diranersen至3期临床。
智通财经 · 07-14
百健(BIIB.US)：将推进阿尔茨海默病药物Diranersen至3期临床。
FDA批准勃健(BIIB)阿尔茨海默病新药皮下剂型 拓展居家治疗应用场景
金吾财讯 · 07-14
FDA批准勃健(BIIB)阿尔茨海默病新药皮下剂型 拓展居家治疗应用场景
加载更多
公司概况
公司名称：
INVESCO BIOTECHNOLOGY & GENOME ETF
所属市场：
ARCA
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":89.6108,"timestamp":1785528000000,"preClose":91.1048,"halted":0,"volume":2625,"hourTrading":{"tag":"盘后","latestPrice":89.68,"preClose":89.6108,"latestTime":"19:34 EDT","volume":12,"amount":1073.7464,"timestamp":1785540842277,"change":0.0692,"changeRate":0.000772,"amplitude":0},"delay":0,"changeRate":-0.01639869688534523,"floatShares":3140000,"shares":3140000,"eps":1.793292,"marketStatus":"休市中","change":-1.494,"latestTime":"07-31 16:00:00 EDT","open":89,"high":89.68,"low":88.62,"amount":234220.21875,"amplitude":0.011635,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":91.1048,"sharesOutstanding":3180000,"nav":91.15695,"aum":287144392.5,"dividendRate":0.017284,"bidAskSpread":0.002546,"postHourTrading":{"tag":"盘后","latestPrice":89.68,"preClose":89.6108,"latestTime":"19:34 EDT","volume":12,"amount":1073.7464,"timestamp":1785540842277,"change":0.0692,"changeRate":0.000772,"amplitude":0},"volumeRatio":0.29962332485607057,"impliedVol":0.2041,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/PBE","defaultTab":"news","newsList":[{"id":"2656139948","title":"安进：部分数据已遭窃取，其中包括专有数据、患者受保护健康信息及其他信息。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656139948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656139948?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:12","pubTimestamp":1785528741,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","IE00B4R5TH58.HKD","PJP","BK4581","LU1023059063.AUD","LU1057294990.SGD","BK4566","BIB","LU0109394709.USD","LU1061106388.HKD","BK4534","BBH","LU1983299246.USD","BK4585","SG9999001440.SGD","BK4599","LU0122379950.USD","LU0058720904.USD","LU2242646821.SGD","IE0009355771.USD","LU2468319806.SGD","LU0289739699.SGD","BK4139","LU0889565916.HKD","AMGN","IBB","IE00B2B36J28.USD","LU2112291526.USD","LU0868494617.USD","BK4533","PBE","LU1571399168.USD","LU2242652126.USD","TBXU","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU2089984988.USD","LU0320765992.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399697","title":"安进：相关调查仍在进行中。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399697","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656399697?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:06","pubTimestamp":1785528374,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LU2468319806.SGD","IBBQ","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4566","BK4534","IE00B2B36J28.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","BBH","BK4585","IE0009355771.USD","BK4533","TBXU","LU0868494617.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU2112291526.USD","LU2089984988.USD","LU0889565916.HKD","LU0109394709.USD","LU0289739699.SGD","LU0320765992.SGD","LU1061106388.HKD","LU2242652126.USD","BK4599","IBB","LU0058720904.USD","AMGN","LU0122379950.USD","LU1571399168.USD","BK4581","PBE","BIB","IE0002141913.USD","PJP","IE00BFTCPJ56.SGD","BK4139","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656996923","title":"安进：预计这一事件不会对公司财务状况或经营业绩产生重大影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656996923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656996923?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:05","pubTimestamp":1785528336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023059063.AUD","LU2112291526.USD","IE00B2B36J28.USD","BK4585","IE0009355771.USD","BK4139","LU2468319806.SGD","PBE","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4534","IBB","LU0109394709.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4533","BBH","TBXU","LU0058720904.USD","IBBQ","LU2242646821.SGD","SG9999001440.SGD","LU0289739699.SGD","LU1057294990.SGD","BK4566","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4581","LU1571399168.USD","BIB","IE00B4R5TH58.HKD","AMGN","LU2242652126.USD","LU1061106388.HKD","LU0868494617.USD","BK4588","BK4599","LU0122379950.USD","LU2089984988.USD","PJP","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656690399","title":"安进在提交给美国证券交易委员会的文件中披露：其云环境中发生专有信息与患者数据泄露事件。截至2026年7月29日判定此次网","url":"https://stock-news.laohu8.com/highlight/detail?id=2656690399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656690399?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:05","pubTimestamp":1785528322,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2089984988.USD","CRWC","LU2242652126.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4566","PJP","LU2242646821.SGD","WCBR","SPAM","LU0122379950.USD","CRWL","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IBB","SOLC","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4581","LU1571399168.USD","IE00B2B36J28.USD","IE0009355771.USD","LU0109394709.USD","SG9999001440.SGD","BK4534","BK4599","IE00BJT1NW94.SGD","LU1983299246.USD","TBXU","IE0002141913.USD","LU0058720904.USD","BIB","AMGN","BK4533","HAKY","LU0868494617.USD","BK4139","PSWD","PBE","LU2468319806.SGD","LU0889565916.HKD","LU1061106388.HKD","IBBQ","BK4585","LU2112291526.USD","UCYB","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175560090","title":"阿尔尼拉姆制药公司公布2026年第二季度财报，并重点回顾近期阶段性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1175560090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175560090?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:02","pubTimestamp":1785412965,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司于近日正式披露了2026年第二季度的财务业绩。与此同时，该公司还着重梳理了在过去一段时间内所取得的各项关键进展。在回顾近期发展时，阿尔尼拉姆强调，其针对多项罕见病及常见疾病的RNAi疗法研究已进入新的里程碑阶段。总体而言，这段时期标志着阿尔尼拉姆在科学探索与商业价值实现上均迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0114720955.EUR","BK4585","ALNY","PBE","GNMX","LU0109394709.USD","LU0889565916.HKD","BK4139","BK4548","LU0882574055.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ9MQY76.HKD","LU1585245621.USD","LU2362541273.HKD","BK4585","LU1674673428.USD","LU1674673691.USD","LU0109394709.USD","LU0079474960.USD","LU1035775433.USD","BIB","LU2417539215.USD","IE00B4R5TH58.HKD","SG9999001176.USD","BK4532","BBH","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4121","LU0289739699.SGD","LU0823416689.USD","IBB","LU0320765992.SGD","SG9999001176.SGD","LU2462157665.USD","LU0889565916.HKD","SG9999013999.USD","LU0432979614.USD","IE00B19Z9Z06.USD","ABCL","LU2324357040.USD","LU1093756325.SGD","IE00B19Z3581.USD","LU2362541513.USD","LU2237438978.USD","SGXZ57979304.SGD","LU0256863811.USD","BK4139","LU2362540622.SGD","BK4567","LU0417517546.SGD","BK4588","VRTX","LU0061475181.USD","LU2236285917.USD","PBE","LU2456880835.USD","TBXU","IBBQ","IE0002270589.USD","LU1430594728.SGD","BK4533","IE00B19Z9P08.USD","IE0002141913.USD","LU1778281490.HKD","GNMX","LU1069344957.HKD","IDNA","BK4535","IE00B19Z3B42.SGD","LU0234570918.USD","IE00BJT1NW94.SGD","LU1093756168.USD","IE00BJJMRZ35.SGD","IE00B894F039.SGD","LU0058720904.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147206442?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0061475181.USD","LU2462157665.USD","LU0432979614.USD","BK4588","LU2362540622.SGD","LU0058720904.USD","IE00B19Z3B42.SGD","LU0234570918.USD","TBXU","IE00BJJMRZ35.SGD","LU1778281490.HKD","BIB","LU2236285917.USD","IDNA","IE00BFTCPJ56.SGD","LU2362541513.USD","VRTX","IE0009355771.USD","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU0289739699.SGD","BK4535","LU0320765992.SGD","BBH","ABCL","GNMX","LU0109394709.USD","LU0889565916.HKD","BK4567","LU1069344957.HKD","LU1093756168.USD","BK4139","IE0002141913.USD","IE00B4R5TH58.HKD","LU0417517546.SGD","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z9Z06.USD","LU2417539215.USD","SG9999013999.USD","SG9999001176.USD","LU0823416689.USD","SG9999001176.SGD","LU1035775433.USD","PBE","LU1674673691.USD","IE00B19Z9P08.USD","BK4585","BK4533","LU2237438978.USD","LU2456880835.USD","BK4121","LU1674673428.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU2324357040.USD","IE00B894F039.SGD","IBBQ","IBB","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0079474960.USD","BK4532","LU0256863811.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173868024","title":"渤健公司：因整合Apellis，截至2026年6月30日止三个月及六个月确认1.532亿美元税前重组净支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1173868024","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173868024?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:46","pubTimestamp":1785321986,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）披露，为推进与Apellis的整合进程，在截至2026年6月30日的三个月及六个月期间内，公司确认了高达1.532亿美元的净税前重组费用。这笔支出旨在优化资源配置，加速业务融合，并应对市场结构性变化。重组举措覆盖了运营调整、人员精简及资产处置等多个方面，以提升长期竞争力。具体而言，这些费用主要源于整合相关活动，包括关闭重叠设施、削减冗余岗位以及处理遗留合同等。公司方面强调，尽管短期面临财务压力，但此举是实现战略协同、释放合并后价值的关键步骤。未来，渤健将继续评估整合进度，并适时调整财务预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","PBE","BK4585","LU0889565916.HKD","BK4533","BK4532","IE00B19Z9P08.USD","BK4588","LU0234570918.USD","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4139","BMED","BIIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147971918","title":"渤健公司：中东冲突未对2026年上半年经营业绩产生实质性影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1147971918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147971918?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:43","pubTimestamp":1785321809,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）最新披露，中东地区的地缘冲突局势，并未对其截至2026年6月30日的三个月及六个月期间的经营业绩，构成任何实质性影响。这一表态，清晰地向市场传递了其业务在外部动荡环境下的韧性。从短期业绩到中期财务状况，这家生物科技巨头均未因该地区的不确定性而遭受显著冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4588","BK4532","LU0320765992.SGD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4139","BMED","IE00B19Z9P08.USD","PBE","BK4533","LU0109394709.USD","BIIB","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138863286","title":"渤健：高剂量Spinraza转换进度超预期，已覆盖所有已上市地区","url":"https://stock-news.laohu8.com/highlight/detail?id=1138863286","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138863286?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:02","pubTimestamp":1785319323,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）宣布，其高剂量Spinraza治疗方案在已上市的所有地理区域中，转换进度均超出公司预期。这一进展表明，患者对该剂型的接受度与医疗系统的适应速度均优于先前的规划。渤健表示，高剂量方案的推广正按计划稳步推进，且在某些市场甚至提前实现了预设目标。这一趋势反映出公司对神经肌肉疾病治疗的持续优化能力，以及市场对创新疗法的积极反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4139","BK4533","BMED","LU0320765992.SGD","LU0889565916.HKD","BIIB","LU0109394709.USD","IE00B19Z9Z06.USD","BK4585","IE00B894F039.SGD","PBE","LU0234570918.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007935","title":"解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007935","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654007935?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:51","pubTimestamp":1785243108,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年的336位上升至今年的224位，成为今年上涨最快的10家公司之一。中国公司中，中国医药集团、上海医药、广药集团3家公司再次入围。《每日经济新闻》记者注意到，位居医疗健康相关企业榜首的是联合健康集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823749452.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823749452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2264538146.SGD","LU0210528500.USD","SG9999002224.SGD","LU2242646821.SGD","LU0823416689.USD","LU1069347547.HKD","LU0557290698.USD","LU0820561909.HKD","IE00BFSS7M15.SGD","IE00BJJMRX11.SGD","LU2403377893.USD","SGXZ51526630.SGD","LU0149725797.USD","IYH","LU0859254822.USD","IE00BVYPNW00.USD","LU1623119135.USD","LU0133085943.USD","LU2237443895.HKD","LU0965509101.SGD","XLV","LU2552382058.USD","LU1674673691.USD","LU0321505439.SGD","LU0238689110.USD","LU0965509010.AUD","LU1868836757.USD","PBE","LU0069063385.USD","LU0342679015.USD","LLII","LU0942090050.USD","LU1496350502.SGD","LU0107464264.USD","LU0124676726.USD","LU2023251221.USD","IE00BLSP4452.SGD","LU0985481810.HKD","03165","CANC","LU0726765562.USD","LU1868837300.USD","BIB","WDNA","LU2491050071.SGD","BK4533","UNHU","RHHBY","LU0395794307.EUR","AGNG","LU0994945656.USD","LU0868494708.USD","LU0354030511.USD","LU1003077747.HKD","LU1496350171.SGD","BK4578","LU2756315318.SGD","LU1854103824.USD","BK4559","LU0057025933.USD","LU0058720904.USD","LU1894683264.USD","LU0006306889.USD","IE0005OL40V9.USD","LU1720051017.SGD","LU2756315664.SGD","SG9999017495.SGD","GB00BDT5M118.USD","LU1935042991.SGD","LU2237443549.SGD","LU1244550577.SGD","LU2087625088.SGD","IE000SO60NU8.SGD","IE00B1XK9C88.USD","LU0225284248.USD","LU1366192091.USD","LU0320765059.SGD","LU0320765489.SGD","LU1732799900.SGD","LU2430703095.HKD","LU2168564065.EUR","LU1674673428.USD","LU0211331839.USD","LU0203345920.USD","LU2360032135.SGD","IE000F7OJYX1.SGD","LU0648001328.SGD","LU0198837287.USD","LU0795875169.SGD","IE00B2B36J28.USD","LU1551013425.SGD","SG9999015952.SGD","LU2596442595.SGD","VHT","IE00B19Z8X17.USD","SGXZ31699556.SGD","MEDX","LU2552382215.SGD","LU0985320562.USD","LU1868836914.USD","LU1037948897.HKD","LU2125154935.USD","IE00BKDWB100.SGD","LU0234570918.USD","LU0077335932.USD","LU2999663052.SGD","LU2462157665.USD","LU2746668974.SGD","LU0266013472.USD","LU2750360641.GBP","LU2237443382.USD","LU2462591277.SGD","LU2471134952.CNY","BK4154","LU2265009873.SGD","LU0130102774.USD","LU0310800379.SGD","BK4139","LU0385154629.USD","LU1814569148.SGD","LU2357627491.SGD","LU0203201768.USD","LU2211815571.USD","SG9999014567.USD","LU2237438978.USD","LU1084165304.USD","LU0210536198.USD","LU0029864427.USD","LU2023250330.USD","LU0965508806.USD","LU2462591350.SGD","LU0882574055.USD","ELIS","LU2357305700.SGD","LU0211328371.USD","LU1430594728.SGD","LU0265550359.USD","LU0528227936.USD","BK4592","BK4568","ILDR","LU2106854487.HKD","IE00BJT1NW94.SGD","LU1032955483.USD","LU1720051108.HKD","IE000MB6IJN5.SGD","LU1323610961.USD","BK4566","LU1712237335.SGD","LU0289961442.SGD","LU1718418525.SGD","IE00BFXG1179.USD","LU2237443622.USD","LU2471134879.HKD","IHF","BK4504","LU1934455863.HKD","LU2168564222.USD","LU0114720955.EUR","LU1261432733.SGD","LU0097036916.USD","LU0211326755.USD","TBXU","LU0417517546.SGD","LU1923622614.USD","PFE","LU0316494557.USD","LU1868836591.USD","IE000M9KFDE8.USD","SG9999014898.SGD","GLAM","SG9999014880.SGD","HRTS","LU1989771016.USD","LU2592432038.USD","IE00BVYPNV92.GBP","LU0683600562.USD","LU0353189763.USD","PPH","IE00BKVL7J92.USD","LU0208291251.USD","LU0823434740.USD","LU2746668461.USD","LLY","LU0511384066.AUD","LU1267930813.SGD","IE00BBT3K403.USD","LU0795875086.SGD","LU2129689514.USD","LU2237443978.SGD","SG9999001176.SGD","LU1941712264.USD","LU2087621335.USD","LU0162691827.USD","LU2324357040.USD","JNJ","LU1548497426.USD","LU1914381329.SGD","TRUH","LU2360106947.USD","LU1988902786.USD","LU1280957306.USD","LU1699723380.USD","LLYX","LU1571399168.USD","LU2487616109.SGD","LU1121112475.USD","SG9999014559.SGD","LU2456880835.USD","IE00B42XCP33.USD","LU0109391861.USD","LU2168564495.EUR","LU2505996509.AUD","LU0965509283.SGD","MRK","IE0004445239.USD","LU1061106388.HKD","LU0949170772.SGD","LU1732800096.USD","UNHW","LU2111349929.HKD","04332","TMED","LU0943347566.SGD","LU1894683348.USD","LU0786609619.USD","LU0052756011.USD","LU0203347892.USD","THNR","LU1074936037.SGD","LU2129689431.USD","LU1119994496.HKD","LU2750360997.AUD","IE0009355771.USD","LU1201861249.SGD","LU0466842654.USD","LU1989772923.USD","LU2361045086.USD","LU0976567544.SGD","LU2133065610.SGD","LU0289739343.SGD","LU0306807586.USD","LU0321505868.SGD","LU2491050154.USD","LU0011850046.USD","LU2954938101.SGD","LU2430703251.USD","LU0345769128.USD","LU0170899867.USD","LU0477156953.USD","IBBQ","IE0004445015.USD","UNHG","LU0079474960.USD","LU2271345857.HKD","IE00BGHQF631.EUR","BK4516","LU2361044865.SGD","IE0002141913.USD","LU1934455194.USD","LU1037948541.HKD","LU0098860793.USD","IE00B7KXQ091.USD","LU0426417589.USD","LU1267930227.SGD","LU0354030438.USD","SG9999014542.SGD","LU0158827948.USD","LU1023059063.AUD","LU2063271972.USD","IE00BSNM7G36.USD","LU1883839398.USD","LU0070302665.USD","IE00B3PB1722.GBP","LU0708994859.HKD","LU0061475181.USD","IE0001KFT4U8.USD","LU0861579265.USD","LU0432979614.USD","LU2237443465.HKD","LU2461242641.AUD","LU0187121727.USD","PAWZ","LU0158827781.USD","IE00B19Z9Z06.USD","LU2552382132.HKD","LU1267930573.SGD","LU0122379950.USD","LU1585245621.USD","IE00BLSP4239.USD","LU2213496289.HKD","LU0320765992.SGD","SG9999018857.SGD","LU0251132253.USD","BK4581","SG9999015341.SGD","LU1162221912.USD","LU2023250843.SGD","LU1093756168.USD","LU1629891620.HKD","LU0289739699.SGD","LU1228905037.USD","IXJ","LU1244550221.USD","LU1043141123.HKD","IE00B19Z3B42.SGD","LU2362540622.SGD","BK4007","SG9999014914.USD","LU0306806265.USD","UNH","LU0545039389.USD","LU1983299246.USD","LU0640476718.USD","LU1791710582.SGD","BK4588","LU0553294199.USD","LU0310800965.SGD","IE0002270589.USD","IE00BDGV0183.EUR","LU0689626769.HKD","FTXH","BK4599","MEDI","LU1232071149.USD","LU0868494617.USD","LU0889565916.HKD","LU0912757837.SGD","NVOH","LU2505996681.GBP","BK4585","LU0820562030.AUD","LU0882574139.USD","BK4532","LU0820561818.USD","LU1221951046.USD","LU0889566641.SGD","LU1221951129.SGD","LU2125154778.USD","NVOX","LU0787776722.HKD","ABBV","LU0426412945.USD","IBB","IE00BK4W5L77.USD","LU1778281490.HKD","ELIL","IE00B7SZLL34.SGD","IE00BN8TJ469.HKD","LU0310799852.SGD","LU1804176565.USD","LU1145028129.USD","LU2168563687.JPY","BBH","LU0225283273.USD","IE00B4JS1V06.HKD","LU1093756325.SGD","LU1267930730.SGD","LU0256863811.USD","IE00B775H168.HKD","LU1066051811.HKD","MHIP","LU2468319806.SGD","IE000WAW04H5.SGD","IHE","SG9999013999.USD","LU1116320901.HKD","NVO","LU1066051498.USD","SGXZ81514606.USD","LU0708995401.HKD","LU1035773651.USD","LU1267930490.SGD","LU0265550946.USD","BK4534","LU2471134796.USD","LU0323591593.USD","SG9999002232.USD","LU2347655156.SGD","LU0353189680.USD","SG9999015978.USD","LU1917777945.USD","LU0689472784.USD","LU1989772840.SGD","IE00BWXC8680.SGD","LU1934455277.USD","SG9999014906.USD","SG9999015986.USD","LU0456855351.SGD","SG9999001440.SGD","OZEM","LU2896262040.SGD","LU2433249047.HKD","SG9999014575.USD","LU2602419157.SGD","LU0072461881.USD","LU0094547139.USD","RXL","IE00BZ1G4Q59.USD","LU1791710400.SGD","LU1929549753.HKD","IE00B19Z9505.USD","LU0130517989.USD","LU0320765646.SGD","LU1064131342.USD","LU2491049909.HKD","LU1941712348.USD","IE00B19Z9P08.USD","LU2236285917.USD","LU0738911758.USD","LU1291159041.SGD","LU2089283258.USD","IE00B19Z3581.USD","LU1069344957.HKD","IE0000B7K699.USD","LU0471298777.SGD","LU0545562505.USD","LU2089284900.SGD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU1116320737.USD","IE00BJJMRZ35.SGD","LU2125909247.SGD","LU2129689605.HKD","LU1153585028.USD","LU2242652126.USD","IE00BN29S564.USD","LU1244550494.USD","IE00B894F039.SGD","LU1506573853.SGD","LU1670628061.USD","LU0672654240.SGD","LU1035775433.USD","LU0496365809.HKD","SG9999001176.USD","NVS","LU2362541513.USD","LU1868837136.USD","LU0345769631.USD","CURE","LU2112291526.USD","SG9999003800.SGD","IE00BJJMRY28.SGD","LU0128525689.USD","LU0980610538.SGD","LU2471134523.USD","LU0203202063.USD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","LU1228905540.USD","GDOC","IE00BK4W5M84.HKD","LU2244417387.USD","LU1974910355.USD","LU2028103732.USD","LU0472753341.HKD","IE000BZT7R73.USD","LU0792757196.USD","LU0128525929.USD","LU0070217475.USD","LU0345770308.USD","LU0053666078.USD","LU0964807845.USD","PJP","LU2417539215.USD","BMED","LU1670627923.USD","LU1127390331.HKD","LU0345770993.USD","IE0034235303.USD","LU0823434583.USD","LU2347655073.USD","IE00BFSS8Q28.SGD","LU1057294990.SGD","LU0106261372.USD","SG9999015945.SGD","LU1196500208.SGD","IE00BKPKM429.USD","AMGN","LU0174119429.USD","BK4550","LU2242649171.HKD","IE00BJLML261.HKD","SG9999015358.SGD","LU0143551892.USD","LU1059921491.USD","LU2168564149.EUR","SGXZ99366536.SGD","LU0211326839.USD","LU1043141396.HKD","LU0234572021.USD","LU0109394709.USD","LU2108987350.USD","LU0096364046.USD","LU2023250504.SGD","LU0225771236.USD","LU1551013342.USD","LU1066053197.SGD","LU2089984988.USD","LU0048584097.USD","LU0661504455.SGD","LU0154236417.USD","IE00B19Z8W00.USD","LU1839511570.USD","IE00BZ9MQY76.HKD","JDOC","SG9999018865.SGD","LU2279689827.SGD","IE00B1BXHZ80.USD","LU0256863902.USD","LU2430703178.SGD","LU1854104046.USD","LU2125909593.SGD","IE00B3T34201.USD","SG9999011175.SGD","LLYZ","FHLC","LU0471298694.HKD","LU1066051225.USD","LU2361044949.HKD","LU0211327993.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百济神州/安进 FIC 双抗，皮下制剂进入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653074709?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2242646821.SGD","III","LU0320765992.SGD","LU1719994722.HKD","LU1969619763.USD","688235","LU1770034418.SGD","LU0122379950.USD","IE00B4R5TH58.HKD","BIB","AMGN","BK4599","LU1303224171.USD","LU2242652126.USD","PBE","06160","KURE","LU1061106388.HKD","BK1500","IBBQ","PJP","LU2328871848.SGD","LU1251922891.USD","BBH","LU1571399168.USD","LU0889565916.HKD","LU2112291526.USD","SG9999001440.SGD","BK4139","ONC","BK4581","BK1583","LU0058720904.USD","LU0307460666.USD","BK4588","IE0002141913.USD","IE0009355771.USD","BK4534","LU0289739699.SGD","LU0588546209.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU2468319806.SGD","TBXU","LU1983299246.USD","IBB","IE00BJT1NW94.SGD","BK1588","BK4585","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653584157?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["APXH","GDOC","IBB","LFSC","SBIO","BK4588","BIOY","BK4585","GSKH","PBE","XLVI","BBP","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129561583","title":"Royalty Pharma宣布2026年第三季度股息派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1129561583","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129561583?lang=zh_cn&edition=full","pubTime":"2026-07-18 04:17","pubTimestamp":1784319458,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc董事会已批准派发2026年第三季度股息，每股A类普通股股息为0.235美元。此次股息将于2026年9月10日支付给截至2026年8月14日营业结束时登记在册的股东。Royalty Pharma成立于1996年，是生物制药领域特许权使用费的最大收购方，也是行业创新的重要资助者。Royalty Pharma构建了一个多元化的特许权组合，使其有权直接基于行业众多领先疗法的总销售额获得收益支付。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","IHE","BK4007","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169524809","title":"卫材：加拿大药品管理机构认可Leqembi临床价值，建议将早期阿尔茨海默病纳入公共医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1169524809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169524809?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:17","pubTimestamp":1784204253,"startTime":"0","endTime":"0","summary":"加拿大药品管理机构已正式认可Leqembi的临床价值，并建议将其纳入公共医保覆盖范围，用于治疗早期阿尔茨海默病。这一积极建议标志着该创新疗法在获得更广泛患者可及性的道路上迈出了关键一步。Leqembi由卫材与渤健公司共同开发，是一种针对阿尔茨海默病潜在病理机制的靶向疗法。加拿大相关机构的认可，是基于其临床试验所展现出的减缓疾病进展的明确证据。此举若最终获得采纳，将显著减轻早期阿尔茨海默病患者及其家庭的经济负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LU0889565916.HKD","LU0109394709.USD","IE00B19Z9Z06.USD","BK4585","BK4588","BK4533","IE00B894F039.SGD","LU0234570918.USD","LU0320765992.SGD","BK4139","IE00B19Z9P08.USD","PBE","BMED","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946677","title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946677","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651946677?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:35","pubTimestamp":1784122530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由 A16z 支持的临床阶段生物制药公司 Braveheart Bio Inc. 于周三向纳斯达克提交了 IPO 申请。这家心血管疾病药物开发商将寻求通过在纳斯达克全球市场销售股份来募集一笔尚未公布具体金额的资金。百健首席执行官克里斯托弗·维巴赫担任 Braveheart 的董事长。Braveheart 报告称，在 2026 年前三个月，其净亏损为 1430 万美元，并创造了约 1100 万美元的收入。相比之下，去年同期的前三个月净亏损为 9.9 万美元。Braveheart 将以股票代码“BRVE”进行交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","PBE","IE00B19Z9P08.USD","BK4139","BK4585","BK4533","IE00B894F039.SGD","LU0109394709.USD","BIIB","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","LU0320765992.SGD","BK4588","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199762348","title":"Leqembi®真实世界领先研究在AAIC® 2026发布：超75%早期阿尔茨海默病患者在平均17个月治疗期内保持稳定，近7%出现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1199762348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199762348?lang=zh_cn&edition=full","pubTime":"2026-07-14 23:16","pubTimestamp":1784042182,"startTime":"0","endTime":"0","summary":"Leqembi®真实世界领先研究在AAIC® 2026年会上公布的数据显示，在该研究中，超过75%的早期阿尔茨海默病患者在接受平均17个月的治疗后病情保持稳定，同时有近7%的患者病情出现改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","BMED","BK4139","BK4585","BK4533","LU0320765992.SGD","BIIB","BK4588","IE00B19Z9Z06.USD","LU0109394709.USD","LU0889565916.HKD","LU0234570918.USD","IE00B894F039.SGD","BK4532","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132952984","title":"渤健公司于AAIC公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益与强劲Tau蛋白降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1132952984","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132952984?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:16","pubTimestamp":1784034993,"startTime":"0","endTime":"0","summary":"渤健公司近日在阿尔茨海默病协会国际会议上公布了其候选药物Diranersen的Celia二期研究数据。结果显示，该药物在治疗早期阿尔茨海默病患者时，不仅带来了具有临床意义的积极结局，更实现了Tau蛋白水平的强劲降低。这一积极信号为针对这一复杂神经退行性疾病的靶向治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","LU0320765992.SGD","BK4585","BK4532","LU0109394709.USD","IE00B894F039.SGD","LU0889565916.HKD","IE00B19Z9P08.USD","BK4588","BIIB","IE00B19Z9Z06.USD","LU0234570918.USD","BMED","BK4533","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651106049","title":"百健(BIIB.US)：将推进阿尔茨海默病药物Diranersen至3期临床。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651106049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651106049?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:15","pubTimestamp":1784034918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","BK4533","IE00B894F039.SGD","LU0109394709.USD","BIIB","BK4585","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","PBE","BK4588","BK4139","BMED","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651754101","title":"FDA批准勃健(BIIB)阿尔茨海默病新药皮下剂型 拓展居家治疗应用场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2651754101","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651754101?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:31","pubTimestamp":1784017876,"startTime":"0","endTime":"0","summary":"本次剂型获批基于严谨的临床对比数据，临床试验证实，Leqembi皮下注射剂型的治疗效果、药效稳定性与原有静脉注射剂型高度一致，疗效水平无显著差异。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302523","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ESALF","LU0234570918.USD","MNTL","BK4532","BK4585","BK4533","BIIB","BK4007","LU0889565916.HKD","LU0109394709.USD","IE00B894F039.SGD","LU0320765992.SGD","LABU","PBE","BMED","IE00B19Z9P08.USD","ESAIY","BK4139","IE00B19Z9Z06.USD","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0002},{"period":"1month","weight":-0.0035},{"period":"3month","weight":0.1246},{"period":"6month","weight":0.0946},{"period":"1year","weight":0.3723},{"period":"ytd","weight":0.0908}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.018649},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.004391},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.002718},{"month":4,"riseRate":0.52381,"avgChangeRate":0.005803},{"month":5,"riseRate":0.619048,"avgChangeRate":0.008753},{"month":6,"riseRate":0.666667,"avgChangeRate":0.018605},{"month":7,"riseRate":0.636364,"avgChangeRate":0.038738},{"month":8,"riseRate":0.571429,"avgChangeRate":0.007712},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.012976},{"month":10,"riseRate":0.52381,"avgChangeRate":-0.006664},{"month":11,"riseRate":0.714286,"avgChangeRate":0.035033},{"month":12,"riseRate":0.47619,"avgChangeRate":0.000122}],"exchange":"ARCA","name":"INVESCO BIOTECHNOLOGY & GENOME ETF","nameEN":"INVESCO BIOTECHNOLOGY & GENOME ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"INVESCO BIOTECHNOLOGY & GENOME ETF,PBE,INVESCO BIOTECHNOLOGY & GENOME ETF股票,INVESCO BIOTECHNOLOGY & GENOME ETF股票老虎,INVESCO BIOTECHNOLOGY & GENOME ETF股票老虎国际,INVESCO BIOTECHNOLOGY & GENOME ETF行情,INVESCO BIOTECHNOLOGY & GENOME ETF股票行情,INVESCO BIOTECHNOLOGY & GENOME ETF股价,INVESCO BIOTECHNOLOGY & GENOME ETF股市,INVESCO BIOTECHNOLOGY & GENOME ETF股票价格,INVESCO BIOTECHNOLOGY & GENOME ETF股票交易,INVESCO BIOTECHNOLOGY & GENOME ETF股票购买,INVESCO BIOTECHNOLOGY & GENOME ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}